Michael Nsaka

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Could calcitonin gene-related peptide inhibitors prevent status epilepticus?

Could calcitonin gene-related peptide inhibitors prevent status epilepticus?

Journal: Epilepsia

Published: April 20, 2026

Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.

Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.

Journal: The journal of headache and pain

Published: April 12, 2024

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.

Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.

Journal: The journal of headache and pain

Published: January 09, 2024

Hypnic Headache - What do we know in 2022?

Hypnic Headache - What do we know in 2022?

Journal: Cephalalgia : an international journal of headache

Published: February 14, 2023

Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.

Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.

Journal: Brain and behavior

Published: April 29, 2022

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.

Journal: The journal of headache and pain

Published: March 28, 2022

Response to the Letter to the Editor by Arshad and Bronstein "Motion perception in vestibular migraine".

Response to the Letter to the Editor by Arshad and Bronstein "Motion perception in vestibular migraine".

Journal: European journal of neurology

Published: August 05, 2021

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.

CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.

Journal: The journal of headache and pain

Published: July 19, 2021

Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross-sectional study.

Sensitized rotatory motion perception and increased susceptibility to motion sickness in vestibular migraine: A cross-sectional study.

Journal: European journal of neurology

Published: February 01, 2021

Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study.

Reduced vestibular perception thresholds in persistent postural-perceptual dizziness- a cross-sectional study.

Journal: BMC neurology

Published: January 07, 2021

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.

Journal: The journal of headache and pain

Published: March 26, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026